Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
about
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaImpact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing ratsThe role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryClinical review: kinase inhibitors: adverse effects related to the endocrine system.Targeting developmental pathways in children with cancer: what price success?Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisPediatric chronic myeloid leukemia is a unique disease that requires a different approachImatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.Management of chronic myeloid leukemia in childhood.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia.Pharmacology and pharmacokinetics of imatinib in pediatric patients.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Adverse effects of imatinib in children with chronic myelogenous leukemia.Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.Optimal management for pediatric chronic myeloid leukemia.Imatinib Inhibits GH Secretion From Somatotropinomas
P2860
Q27025242-0088DA31-931C-455B-AD5D-CF2888AA2300Q28548625-2265CF25-84F1-495C-AE45-6E84D37CD574Q35634865-2FB9B6BE-CDF7-4666-89E7-42D55FE32B8FQ36736494-D48AA270-8651-42E2-A003-6DF585DCA1C1Q36905620-43E58FD7-B0E4-454F-82D9-CFA0A0F3B2D1Q36928803-6196D384-D3B2-4662-9B8B-854BB09811E1Q37025981-497FE550-62B8-4FA1-A11B-430A1336A289Q37989418-A9906E3B-921C-490A-A89C-A2634DFA8506Q37991223-ABD965DC-87CA-417D-8833-133FF4B023B5Q38698520-A888794B-B8C0-4B7E-81F4-E7BBDACFBA12Q38813874-0228BEE3-7E80-47A2-AA5F-25DF05406B76Q39484798-5177E027-1AF4-4394-8B8A-F882D75291FAQ43156043-0218B1FF-018D-4589-84B3-8A20337D45C4Q48146200-77FFC18F-4231-47E5-8232-E56F31C11B8BQ50094239-3C38DE76-4275-4677-BC9E-D0E919C03FB8Q51072279-EA8D87B2-D7F7-49E3-904B-1067E7BDD93BQ51562409-54787719-E413-4B8D-8EF3-12A67947C736Q52893458-1E994141-64A0-44A9-B1D1-73BE431035C4Q55034870-C68B48F9-AE4B-4BB4-BDED-96019CC8F1D5Q58633992-DC741CBC-5210-4281-BE7C-BC6DCC2AAF03
P2860
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@en
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@nl
type
label
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@en
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@nl
prefLabel
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@en
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@nl
P2093
P2860
P356
P1476
Acquired growth hormone defici ...... sine kinase inhibitor therapy.
@en
P2093
Bahareh Schweiger
Michael Wang
Susan L Hobernicht
P2860
P304
P356
10.1002/PBC.22945
P577
2010-12-22T00:00:00Z